"The presence of HIV should not actually affect the efficacy of these drugs, so there is no need to include a drug that acts on both - you just eradicate the HCV with HCV drugs, and manage HIV with HIV drugs."
Curious to see the co-effected trails on GS7977 that support your above hypothesis? Please provide links.
IMO the major issue at the moment is cash, Biotron doesn't have enough in order progress trails accordingly- It's that simple. I'm also concerned over the HIV trails, and the lack of feedback/ excitement shown from MGMT
forget hcv, concentrate on hiv, page-9
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.7¢ |
Change
-0.001(3.57%) |
Mkt cap ! $24.36M | |||
| Open | High | Low | Value | Volume |
| 2.7¢ | 2.7¢ | 2.7¢ | $1.136K | 42.07K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1950508 | 2.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.7¢ | 199924 | 1 |
View Market Depth
| Last trade - 14.29pm 30/08/2024 (20 minute delay) ? |
| BIT (ASX) Chart |